<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01875809</url>
  </required_header>
  <id_info>
    <org_study_id>RDN-Cathecholamines-1</org_study_id>
    <nct_id>NCT01875809</nct_id>
  </id_info>
  <brief_title>Impact of Catecholamine Spill-over on Outcome After RDN and EP Ablation</brief_title>
  <acronym>RDN-Cath-1</acronym>
  <official_title>Impact of Patient-specific and Procedural Characteristics Like Catecholamine Spill-over on the Long-term Outcome After Renal Denervation and EP Ablation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Witten/Herdecke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Witten/Herdecke</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite a rapidly increasing number of renal denervation (RDN) procedures, only little is
      known regarding the patient or procedural characteristics influencing the outcome. None of
      the detectable variables like number of ablation points, temperature rise, impedance drop,
      have been shown to correlate with the blood pressure (BP) reduction. In this study, the
      investigators assess different patient and procedural characteristics, like exact patient
      medication, stress hormones, heart rate variability, and focus on the change of the
      catecholamine spill-over, and the impact on BP and heart rate after RDN and after EP
      ablation. The investigators hypothesize the correlation between reduction of catecholamine
      spill-over due to denervation and the BP reduction. In this study, the investigators will
      assess 40 patients undergoing RDN and 40 patients undergoing EP ablation.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2013</start_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Catecholamine norepinephrine and epinephrine (pg/ml)</measure>
    <time_frame>2 years</time_frame>
    <description>Measurement the differences of norepinephrine and epinephrine (pg/ml) in the renal vein and artery before and after the ablation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact of the ablation on 24-hour blood pressure (mmHg) and heart rate (beats/min)</measure>
    <time_frame>2 years</time_frame>
    <description>Complete measurement of 24-hour systolic, diastolic, and mean arterial blood pressure (mmHg) and heart rate (beats/min)before and after ablation</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Renal denervation (RDN)</arm_group_label>
    <description>Change of catecholamine spill-over during RDN</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Electrophysiology (EP) Ablation</arm_group_label>
    <description>Change of catecholamine spill-over during EP ablation</description>
  </arm_group>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood for measurement of catecholamines.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing renal denervation or EP Ablation with informed consent fulfilling all
        inclusion criteria and None of the exclusion criteria.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  medically-indicated renal denervation

          -  Age over 18 years

          -  written informed consent

        Exclusion Criteria:

          -  pregnancy

          -  expected compliance problems

          -  current participation in other studies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Klaus A Tiroch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Wittn/Herdecke</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Klaus A Tiroch, MD</last_name>
    <phone>+49-202-896-5698</phone>
    <email>klaus.tiroch@helios-kliniken.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jacek Szymanski, MD</last_name>
    <phone>+49-202-896-5377</phone>
    <email>jacek.szymanski@helios-kliniken.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>HELIOS Klinikum</name>
      <address>
        <city>Wuppertal</city>
        <state>Nordrhein-Westfalen</state>
        <zip>42117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaus A Tiroch, MD</last_name>
      <phone>+49-202-896-5698</phone>
      <email>klaus.tiroch@helios-kliniken.de</email>
    </contact>
    <contact_backup>
      <last_name>Jacek Szymanski, MD</last_name>
      <phone>+49-202-896-5377</phone>
      <email>jacek.szymanski@helios-kliniken.de</email>
    </contact_backup>
    <investigator>
      <last_name>Klaus A Tiroch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc Vorpahl, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jacek Szymanski, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Armin Sause, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Osman Tutdibi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sebastian Winn, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ina Schmitz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.helios-kliniken.de/klinik/wuppertal/fachabteilungen/herzzentrum/herzzentrum-wuppertal/kardiologie/leistungsspektrum.html</url>
    <description>Patient information regarding our RDN program</description>
  </link>
  <link>
    <url>http://www.helios-kliniken.de/klinik/wuppertal/fachabteilungen/herzzentrum/herzzentrum-wuppertal/kardiologie/leistungsspektrum/herzkatheterlabor.html</url>
    <description>Description of the RDN procedure at our center</description>
  </link>
  <reference>
    <citation>Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011 May;57(5):911-7. doi: 10.1161/HYPERTENSIONAHA.110.163014. Epub 2011 Mar 14.</citation>
    <PMID>21403086</PMID>
  </reference>
  <reference>
    <citation>Symplicity HTN-2 Investigators, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, BÃ¶hm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010 Dec 4;376(9756):1903-9. doi: 10.1016/S0140-6736(10)62039-9. Epub 2010 Nov 17.</citation>
    <PMID>21093036</PMID>
  </reference>
  <results_reference>
    <citation>Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med. 2009 Aug 27;361(9):932-4. doi: 10.1056/NEJMc0904179.</citation>
    <PMID>19710497</PMID>
  </results_reference>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2013</study_first_submitted>
  <study_first_submitted_qc>June 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2013</study_first_posted>
  <last_update_submitted>June 11, 2013</last_update_submitted>
  <last_update_submitted_qc>June 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Witten/Herdecke</investigator_affiliation>
    <investigator_full_name>Tiroch, Klaus</investigator_full_name>
    <investigator_title>Privatdozent Dr. med.</investigator_title>
  </responsible_party>
  <keyword>RDN</keyword>
  <keyword>renal denervation</keyword>
  <keyword>catecholamine</keyword>
  <keyword>spill-over</keyword>
  <keyword>blood pressure</keyword>
  <keyword>electrophysiology</keyword>
  <keyword>ablation</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

